AusBiotech is set to showcase the globally-recognised strength of the Australian clinical trials sector during JP Morgan week in January 2021.
The annual event is an important opportunity for investors and industry to engage with each other across the globe, and AusBiotech’s virtual showcase will highlight the advantages of partnering with Australian life science companies.
Australia’s clinical trials sector is open for research. The robust regulatory environment combined with incentives for research and development, strong networks and excellent engagement with clinicians/researchers, access to established and proven pathways of obtaining high quality clinical data recognised by US and European regulators, and other global institutions, and the speed with which trials can be initiated, makes Australia an attractive place to do business.
The showcase will also highlight how Australia’s R&D Tax Incentive, a cornerstone for innovation, actively supports innovative local companies with their R&D and offers an attractive environment for companies from around the world to develop their intellectual property to Australia.
The distinct perspectives across the programme highlight Australia’s cross-border relationships, investment opportunities, and research and regulatory capabilities. The programme includes:
- Capitalising on the strengths of the Australian bio-economy, Lorraine Chiroiu, CEO, AusBiotech
- Opportunities in Australia’s healthcare sector, Nicola Watkinson, General Manager, The Americas, Austrade
- Australia as a destination for clinical trials – capabilities and infrastructure, Professor Megan Robertson, Group Chief Research Officer, St Vincent’s Health Australia and Chair,
- Conducting clinical trials in Australia – ethics, approvals and lead times, Kylie Sproston, Chief Executive Officer, Bellberry
- How state government is supporting clinical trials, Anne O’Neill, Director Enterprise and International Partnerships, NSW Office for Health and Medical Research, Ministry of Health
- How Australia supports research and development, Hank Sciberras, Partner, Global Investment and Innovation Incentives, Deloitte Tax Services
- Why Australia should be a priority market for medical innovation – Brandwood CKC
- Clinical trials in action, a case study.
Australia has been amongst the globe’s lesser COVID-19-impacted countries, providing the opportunity to start and continue clinical trials and medical research through the pandemic. Through careful management of the pandemic, clinical trials are not only giving Australian patients access to new therapies, vaccines and medical devices, but also giving the country a comparative advantage as a destination for clinical trials from around the globe.
Intended for international audiences, the showcase is free of charge, and will be broadcast live on Thursday, 14th January, 3:00pm – 5:00pm (San Francisco/PST)/ Friday, 15th January, 10:00am – 12:00pm (Melbourne/AEDT).
Interested parties are encouraged to share with their networks and/or register for the Australian Showcase .
